Product revenue and reserves

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Product revenue and reserves

Product revenue and reserves

For the years ended December 31, 2023 and 2022, the Company recorded $29.1 million and $2.7 million, respectively, of product revenue. Product revenue by therapy represents:

	For the year ended December 31,
	2023		2022
ZYNTEGLO	$	16,692	$	2,739
SKYSONA	12,373		—
Total product revenue	$	29,065	$	2,739

Two individual customers accounted for 49% and 35% of product revenue for the year ended December 31, 2023, and one individual customer accounted for 100% of product revenue for the year ended December 31, 2022.

The Company considers there to be revenue concentration risks for customers that represent product revenues that exceed 10% of total product revenue. The concentration of the Company’s product revenue with a particular customer may have a material adverse effect on the Company’s revenue and results of operations if sales with the respective customer experience difficulties. All product revenue during 2023 and 2022 were within the United States and Europe, respectively.

The following table summarizes an analysis of the change in reserves for gross to net deductions for the periods indicated:

	Total
Balance at December 31, 2022	$	—
Provision for rebates	5,365
Payments/credits	—
Balance at December 31, 2023	$	5,365